98%
921
2 minutes
20
This study aims to identify and validate potential endogenous biomarkers for triple-negative breast cancer (TNBC). TNBC microarray data (GSE38959, GSE53752) were retrieved from the Gene Expression Omnibus (GEO) database, and principal component analysis (PCA) was performed to evaluate the reliability of the data. The microarray datasets were merged, and differentially expressed genes (DEGs) were identified using R software. Functional enrichment analysis of the DEGs was conducted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The most disease-relevant module was identified through Weighted Gene Co-expression Network Analysis (WGCNA), and genes within this module were intersected with the DEGs. The intersecting genes underwent Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis to minimize errors and identify TNBC-specific genes. Sensitivity and survival analyses were performed on the identified specific genes. There were 10 TNBC-specific genes identified: RRM2, DEPDC1, FIGF, TACC3, E2F1, CDO1, DST, MCM4, CHEK1, and PLSCR4. RT-qPCR analysis showed significant upregulation of CDO1, MCM4, DEPDC1, RRM2, and E2F1 in MDA-MB-231, CAL-148, and MFM-223 compared to MCF-10A. Our findings provide new insights into TNBC pathogenesis and potential therapeutic strategies, with important clinical implications for further understanding TNBC mechanisms and developing innovative treatments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/18758592241308738 | DOI Listing |
J Cell Mol Med
September 2025
College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Berberine (BBR) is an isoquinoline alkaloid with a variety of biological activities, including anti-microbial and anti-tumoral activities. However, the cellular targets of BBR and the roles of BBR in the radiosensitivity of breast cancer cells are not well defined. In this study, we investigated the effects of BBR on the radiosensitivity of BT549 triple-negative breast cancer cells.
View Article and Find Full Text PDFToxicol Appl Pharmacol
September 2025
Department of Radiation Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China. Electronic address:
Triple-negative breast cancer (TNBC) was a highly aggressive and metastatic subtype of breast cancer characterized by a poor prognosis and limited treatment options. Clarifying the underlying molecular mechanisms was of significant clinical importance. In this study, we We plotted Kaplan-Meier survival curves based on data from the Human Cancer Database and found that elevated CYPJ expression increased patient mortality risk and decreased survival rates.
View Article and Find Full Text PDFEur J Pharmacol
September 2025
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, PR China. Electronic address:
We previously screened a peptide PDBAG1 that remarkably inhibited triple-negative breast cancer, and found that its target was C1QBP. Recently, C1QBP has been reported as a potential tumor marker in ovarian cancer, which of the mortality rate ranks first among malignant tumors of the female reproductive tract. However, it is unclear whether and how PDBAG1 plays a regulatory role in ovarian cancer.
View Article and Find Full Text PDFAnn Diagn Pathol
September 2025
Associate Professor of Anatomic Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address:
Ann Surg Oncol
September 2025
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.